NovAccess Global Receives FDA Approval of Orphan Drug Application for TLR-AD1
NovAccess Global Inc. announced the approval of its application with the U.S. Food and Drug Administration (FDA) for Orphan Drug Designation (ODD) for TLR-AD1, a vaccine immunotherapy…
Read More...
Read More...